Chinese Wuhan Virus Thread


Senior member
Dec 3, 2017

China says Covid deaths down by nearly 80pc

The number of daily Covid-19 deaths in China has fallen by nearly 80 per cent since the start of the month, authorities have said, in a sign that the country’s unprecedented infection surge may have started to abate.

A wave of virus cases has washed over the world’s most populous nation since Beijing abruptly ended its zero-Covid policy last month.

Beijing’s figures are believed to only represent a fraction of the true toll, given China’s narrow definition of a Covid death and official estimates that swathes of the population have been infected.

The CDC last week said nearly 13,000 people had died from Covid-related illnesses between January 13 and 19, adding to a previous announcement that around 60,000 people had succumbed to the virus in hospitals in just over a month.

But recent local government announcements and media reports have indicated that the wave may have started to recede since peaking in late December and early January when hospitals and crematoriums were packed.

There were 896 deaths attributable to the virus in hospitals on Monday, a decline of 79pc from January 4, China’s Center for Disease Control and Prevention (CDC) said in a statement on Wednesday.

Severe cases in hospitals also dwindled to 36,000 by Monday, representing a 72pc drop from a high of 128,000 on January 5, the CDC said.
The announcement came during China’s biggest public holiday, the Lunar New Year, with authorities previously warning that the period of mass travel and social gatherings may trigger a renewed spike in infections.

As of Tuesday, around 664 million trips had been taken nationwide during the Lunar New Year travel period, state broadcaster CCTV reported, citing official figures.


Senior member
Dec 3, 2017

Union Health Minister Dr. Mansukh Mandaviya unveils world’s first intranasal COVID19 vaccine, iNNCOVACC in the presence of Union Minister of State (IC) for Science and Technology Dr Jitendra Singh
Being the world’s first intra-nasal COVID19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat: Dr. Mansukh Mandaviya
“India’s vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines”
India has taken a lead in developing vaccines and medicines for diseases common in the developing world: Dr Jitendra Singh​

Dr. Mansukh Mandaviya, Union Minister of Health & Family Welfare unveiled the iNNCOVACC COVID19 vaccine today in the presence of Union Minister of State (IC) for Science and Technology, Dr Jitendra Singh. iNNCOVACC is the world’s first intranasal COVID19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose. It is developed by Bharat Biotech International Limited (BBIL) in collaboration with Biotechnology Industry Research Assistance (BIRAC), a PSU under the Dept of Biotechnology, Ministry of Science and Technology.


Expressing his elation at the event, Dr Mandaviya said that over 65% of vaccines supplied in the world are from India. Congratulating the BBIL team and the dept of Biotech for bringing about the world’s first nasal vaccine, he stated that “being the world’s first intra-nasal COVID19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat”.


The Union Health Minister added that India’s vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines. He also highlighted that BBIL in collaboration with ICMR introduced COVAXIN in India within a month of the launch of first COVID vaccine in the world.

Congratulating BBIL for innovating another vaccine in collaboration with BIRAC, Dr Jitendra Singh said that “India has taken a lead in developing vaccines and medicines for diseases common in the developing world”. He credited Hon’ble Prime Minister's personal intervention and regular monitoring for inspiring and enabling the launching of "Mission Covid Suraksha" which has not only strengthened AatmaNirbhar Bharat but also bolstered India’s status as a worldwide vaccine development and manufacturing centre, thus showcasing the strength of India's Science and Technology capabilities. “Next step would be to develop vaccines for non-communicable diseases”, he added.


He also stated that ZyCoV-D, the world’s first and India’s indigenously developed DNA based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above, was also developed in partnership with the Department of Biotechnology in the Ministry of Science & Technology under ‘Mission Covid Suraksha’ through BIRAC.

iNCOVACC is a cost effective covid vaccine which does not require syringes, needles, alcohol wipes, bandage, etc, saving costs related to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for injectable vaccines. It utilizes a vector-based platform, which can be easily updated with emerging variants leading to large scale production, within a few months. These rapid response timelines combined with the ability of cost effective and easy intranasal delivery, makes it an ideal vaccine to address future infectious diseases.

A rollout of iNCOVACC is expected to begin in private hospitals that have placed advance orders. Initial manufacturing capacity of several million doses per annum has been established, this can be scaled up to a billion doses as required. iNCOVACC is priced at INR 325/dose for large volume procurement by State Governments and Govt of India.

Dr Rajesh Gokhale, Secretary, Dept of Biotechnology, Shri Rajesh Kumar Pathak, Secretary, Technology Development Board and other senior officials of the Ministry were present on the occasion. Dr Krishna Ella, Co-Founder & Executive Chairman, Bharat Biotech and Smt. Suchitra Ella, Co-Founder and MD, Bharat Biotech were also present.
  • Like
Reactions: _Anonymous_


Well-Known member
Jan 2, 2023
Bharat biotech nasal vaccine

this research can lead to a new generation of low-cost biosensors

  • Like
Reactions: BMD and _Anonymous_


Senior member
Dec 4, 2017


Senior member
Dec 3, 2017

India’s Covid vaccination, lockdown saved over 34 lakh lives: Stanford varsity report​

The Covid-19 vaccination programme in India was able to save 3.4 million lives and create a net economic benefit of $15.4 billion by preventing losses, according to a working paper by the Stanford University and Institute for Competitiveness that was released by Union Health Minister Mansukh Mandaviya during his virtual address at “The India Dialog” at the university.

The report looked at three cornerstones of India’s strategy during the pandemic — containment, relief package and vaccine administration.

During the address, Mandaviya said India undertook the world’s biggest vaccination drive, with 97% coverage of the first dose and 90% of the second dose, administering over 2.2 billion doses to those above 12 years.

“The drive focused on equitable coverage for all, hence vaccines were provided free to all citizens. Campaigns and digital tools such as ‘Har Ghar Dastak’, mobile vaccination teams as well as the inception of Co-Win vaccine management platform were leveraged to ensure last-mile delivery,” he said, adding that the success depended on allaying fears and managing misinformation.

The report said the vaccination prevented a total loss of $18.3 billion, with the net benefit standing at $15.4 billion after accounting for the cost of the vaccination drive. The report reflected that the benefits of vaccination exceeded its cost and suggested that vaccination be considered a macroeconomic stabilising indicator contrary to just a health intervention.

The report also stated that the development and manufacturing of the vaccines in the country allowed the government to inoculate a large number of people and also decrease the burden on healthcare systems.

The report said that timely lockdown helped prevent 100,000 to 2 million deaths that would have happened without it. The lockdown, it says, was able to push the peak of infections in the country to September 2020, buying necessary time to revamp health infrastructure.

Giving example of Kerala, the report said measures like contact tracing, mass testing, home quarantine, distribution of essential medical equipment, revamping healthcare infrastructure, and constant coordination among stakeholders at the Centre, state and district levels helped in managing the pandemic. “Given the regional disparities in the country, it is necessary to look into sub-national-level mitigation strategies to provide an overview of the growth rate of the epidemic during different phases of the mitigation strategies deployed by states for sound decision-making,” the report said.

Initiatives of the government such as the Pradhan Mantri Garib Kalyan Ann Yojana have been highlighted by the report as measures to ensure food safety.


Senior member
Dec 22, 2017

China does it again....🤬🤬

The world should quarantine these Filthy Bat🦇 & cockroach 🪳 eaters Chinese....😡😡🤬🤬